327.04MMarket Cap-7704P/E (TTM)
12.380High12.120Low9.55KVolume12.200Open12.000Pre Close116.69KTurnover0.10%Turnover RatioLossP/E (Static)26.88MShares24.00052wk High1.69P/B112.48MFloat Cap11.68052wk Low--Dividend TTM9.25MShs Float24.000Historical High--Div YieldTTM2.17%Amplitude11.680Historical Low12.217Avg Price1Lot Size
Alto Neuroscience Stock Forum
NEWS
Alto Neuroscience Announces Positive Phase 1 Results for ALTO-101, a Novel PDE4 Inhibitor in Development for Schizophrenia
ALTO-101 demonstrated favorable pharmacokinetic and tolerability profile in Phase 1 study
Transdermal formulation provided significantly greater drug exposure with fewer adverse events
Proof-of-concept study for CIAS to start in the first half of 2024
Topline data expected in the second half of 2025
Achievement of target exposure with propri...
No comment yet